Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Post by Chainsawwon Nov 19, 2010 8:50pm
251 Views
Post# 17733046

BROKER SUMMARY NOV 19

BROKER SUMMARY NOV 19House Positions for C:AMF from 20101119 to 20101119
House Bought $Val Ave Sold $Val Ave Net $Net
85 Scotia 163,500 76,295 0.467 25,500 12,097 0.474 138,000 -64,198
7 TD Sec 43,500 21,065 0.484 29,500 13,665 0.463 14,000 -7,400
19 Desjardins 34,966 16,113 0.461 22,166 10,511 0.474 12,800 -5,602
33 Canaccord 30,000 14,516 0.484 22,000 10,477 0.476 8,000 -4,039
79 CIBC 6,500 2,742 0.422 5,100 2,295 0.45 1,400 -447
99 Jitney 1,500 727 0.485 1,500 742 0.495 0 15
1 Anonymous 0 1,000 490 0.49 -1,000 490
2 RBC 0 4,000 1,810 0.453 -4,000 1,810
81 HSBC 0 35,200 17,242 0.49 -35,200 17,242
9 BMO Nesbitt 0 38,500 17,685 0.459 -38,500 17,685
124 Questrade 8,500 3,717 0.437 51,500 24,332 0.472 -43,000 20,615
80 National Bank 10,000 4,500 0.45 62,500 28,329 0.453 -52,500 23,829
TOTAL 298,466 139,675 0.468 298,466 139,675 0.468 0 0
Bullboard Posts